ASCLETIS-B (01672) plans to allocate approximately 4% of the shares for about 69.256 million shares at a net fundraising of around HK$835.3 million.

ASCLETIS-B (01672) announced that on February 3, 2026, the company plans to issue 69.256 million shares, accounting for approximately 6.98% of the total issued shares of the company as of the date of this announcement (which is 992 million shares, excluding 7.0842 million treasury shares). The subscription price for each share is HKD 12.18, which represents a discount of approximately 4.0% compared to the closing price of HKD 12.69 per share on February 2. The expected total proceeds from the subscription is approximately HKD 843.5 million, with expected net proceeds of approximately HKD 835.3 million. It is proposed that around 90% of the net proceeds from the subscription will be used for the preparation, infrastructure and initiation of the global Phase III clinical trial of ASC30, a small molecule oral GLP-1 receptor agonist for the treatment of obesity, while approximately 10% of the net proceeds will be used for working capital and other general corporate purposes.